共 50 条
Novel Therapeutic Targets in Non-small Cell Lung Cancer
被引:117
|作者:
Janku, Filip
[1
,2
]
Garrido-Laguna, Ignacio
Petruzelka, Lubos B.
[2
]
Stewart, David J.
[3
]
Kurzrock, Razelle
机构:
[1] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Phase Clin Trials Program 1, Unit 455, Houston, TX 77030 USA
[2] Charles Univ Prague, Dept Oncol, Fac Med 1, CR-11636 Prague 1, Czech Republic
[3] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
关键词:
Non-small cell lung cancer;
Molecular target;
Mutation;
EGFR;
VEGF;
VEGFR;
KRAS;
BRAF;
PIK3CA;
EML4-ALK;
IGF-1R;
GROWTH-FACTOR-RECEPTOR;
PHASE-III TRIAL;
IN-SITU HYBRIDIZATION;
GENE COPY NUMBER;
EML4-ALK FUSION GENE;
HER2 KINASE DOMAIN;
SOMATIC MUTATIONS;
ACQUIRED-RESISTANCE;
1ST-LINE GEFITINIB;
MOLECULAR PREDICTORS;
D O I:
10.1097/JTO.0b013e31822944b3
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
The development of personalized medicine with a focus on novel targeted therapies has supplanted the one-size-fits-all approach to the treatment of many cancers, including non-small cell lung cancer. Targeted therapies, if given to a patient subpopulation enriched by the presence of relevant molecular targets, can often abrogate cell signaling that perpetuates cancer progression. Critical targets activating procancer pathways include, but are not limited to, epidermal growth factor receptor (EGFR), hepatocyte growth factor receptor (MET), vascular endothelial growth factor (VEGF), VEGF receptor, GTPase KRAS (KRAS), receptor tyrosine protein kinase erbB-2 (HER2), echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4ALK), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA), serine/threonine-protein kinase B-raf (BRAF), and insulin-like growth factor 1 receptor (IGF1R). Some target-directed therapies, such as epidermal growth factor receptor tyrosine kinase inhibitors and anti-VEGF monoclonal antibody, have already been approved for clinical use. Others, such as those targeted to MET, VEGFR, HER2, PIK3CA, and IGF-1R, are in clinical testing. This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy.
引用
收藏
页码:1601 / 1612
页数:12
相关论文